Literature DB >> 10887202

Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties.

M Haniu1, P Denis, Y Young, E A Mendiaz, J Fuller, J O Hui, B D Bennett, S Kahn, S Ross, T Burgess, V Katta, G Rogers, R Vassar, M Citron.   

Abstract

The cerebral deposition of amyloid beta-peptide is an early and critical feature of Alzheimer's disease. Amyloid beta-peptide is released from the amyloid precursor protein by the sequential action of two proteases, beta-secretase and gamma-secretase, and these proteases are prime targets for therapeutic intervention. We have recently cloned a novel aspartic protease, BACE, with all the known properties of beta-secretase. Here we demonstrate that BACE is an N-glycosylated integral membrane protein that undergoes constitutive N-terminal processing in the Golgi apparatus. We have used a secreted Fc fusion-form of BACE (BACE-IgG) that contains the entire ectodomain for a detailed analysis of posttranslational modifications. This molecule starts at Glu(46) and contains four N-glycosylation sites (Asn(153), Asn(172), Asn(223), and Asn(354)). The six Cys residues in the ectodomain form three intramolecular disulfide linkages (Cys(216)-Cys(420), Cys(278)-Cys(443), and Cys(330)-Cys(380)). Despite the conservation of the active site residues and the 30-37% amino acid homology with known aspartic proteases, the disulfide motif is fundamentally different from that of other aspartic proteases. This difference may affect the substrate specificity of the enzyme. Taken together, both the presence of a transmembrane domain and the unusual disulfide bond structure lead us to conclude that BACE is an atypical pepsin family member.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10887202     DOI: 10.1074/jbc.M002095200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

Review 1.  Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease.

Authors:  C Dingwall
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 2.  Membrane proteases in the bacterial protein secretion and quality control pathway.

Authors:  Ross E Dalbey; Peng Wang; Jan Maarten van Dijl
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

Review 3.  Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

Authors:  Xiaoyang Luo; Riqiang Yan
Journal:  Int J Clin Exp Pathol       Date:  2010-07-08

4.  BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice.

Authors:  Masuo Ohno; Sarah L Cole; Marina Yasvoina; Jie Zhao; Martin Citron; Robert Berry; John F Disterhoft; Robert Vassar
Journal:  Neurobiol Dis       Date:  2006-12-20       Impact factor: 5.996

Review 5.  Beta-secretase: structure, function, and evolution.

Authors:  Chitra Venugopal; Christina M Demos; K S Jagannatha Rao; Miguel A Pappolla; Kumar Sambamurti
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

Review 6.  The beta-secretase, BACE: a prime drug target for Alzheimer's disease.

Authors:  R Vassar
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

7.  The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.

Authors:  Xiqian Lan; Tomomi Kiyota; Richa Hanamsagar; Yunlong Huang; Scott Andrews; Hui Peng; Jialin C Zheng; Susan Swindells; George A Carlson; Tsuneya Ikezu
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-09       Impact factor: 4.147

Review 8.  β-Secretase: its biology as a therapeutic target in diseases.

Authors:  Haibo Wang; Rena Li; Yong Shen
Journal:  Trends Pharmacol Sci       Date:  2013-02-27       Impact factor: 14.819

9.  Rapid and direct transport of cell surface APP to the lysosome defines a novel selective pathway.

Authors:  Angela Lorenzen; Jonathan Samosh; Kenneth Vandewark; Pieter H Anborgh; Claudia Seah; Ana C Magalhaes; Sean P Cregan; Stephen S G Ferguson; Stephen H Pasternak
Journal:  Mol Brain       Date:  2010-04-21       Impact factor: 4.041

10.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.